Particle therapy for non-small cell lung tumors: Where do we stand? A systematic review of the literature

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Wink, Krista ^a   Roelofs, Erik ^a   Solberg, Timothy ^b   Lin, Liyong ^b   Simone, Charles B ^b   Jakobi, Annika ^c,d   Richter, Christian ^c,d,e   Lambin, Philippe ^a   Troost, Esther G C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c Helmholtz Zentrum Dresden Rossendorf   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

3D CRT; C ion; IMPT; IMRT; NSCLC; PBS; Photon; Proton; PSPT; Radiotherapy; SBRT

Indexed keywords

FLUORODEOXYGLUCOSE;

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER MODEL; HUMAN; INTENSITY MODULATED PROTON THERAPY; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PARTICLE THERAPY; PASSIVE SCATTERING PROTON THERAPY; PHOTON THERAPY; RADIATION INJURY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

EID: 84907693889     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00292     Document Type: Review

References (60)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA: a cancer journal for clinicians. 2014 Jun 1. PubMed PMID: 24890451.
2. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010 May 1;28(13):2181-90. PubMed PMID: 20351327.
3. Machtay M, Paulus R, Moughan J, Komaki R, Bradley JE, Choy H, et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2012 Apr;7(4):716-22. PubMed PMID: 22425920. Pubmed Central PMCID: 3335930.
4. Kong FM, Zhao J, Wang J, Faivre-Finn C. Radiation dose effect in locally advanced non-small cell lung cancer. Journal of thoracic disease. 2014 Apr;6(4):336-47. PubMed PMID: 24688778. Pubmed Central PMCID: 3968556.
5. van Baardwijk A, Wanders S, Boersma L, Borger J, Ollers M, Dingemans AM, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010 Mar 10;28(8):1380-6. PubMed PMID: 20142596.
6. Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2011 Jul;100(1):76-85. PubMed PMID: 21757247.
7. Hoffmann AL, Troost EG, Huizenga H, Kaanders JH, Bussink J. Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial. International journal of radiation oncology, biology, physics. 2012 Aug 1;83(5):1596-602. PubMed PMID: 22245206.
8. Roelofs E, Engelsman M, Rasch C, Persoon L, Qamhiyeh S, de Ruysscher D, et al. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2012 Jan;7(1):165-76. PubMed PMID: 22071782.
9. Moyers MF, Miller DW, Bush DA, Slater JD. Methodologies and tools for proton beam design for lung tumors. International journal of radiation oncology, biology, physics. 2001 Apr 1;49(5):1429-38. PubMed PMID: 11286851.
10. Park PC, Zhu XR, Lee AK, Sahoo N, Melancon AD, Zhang L, et al. A beam-specific planning target volume (PTV) design for proton therapy to account for setup an 5 d range uncertainties. International journal of radiation oncology, biology, physics. 2012 Feb 1;82(2):e329-36. PubMed PMID: 21703781. Pubmed Central PMCID: 3183263.
11. van Baardwijk A, Tome WA, van Elmpt W, Bentzen SM, Reymen B, Wanders R, et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2012 Nov;105(2):145-9. PubMed PMID: 23068707.
12. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2011 Nov;101(2):240-4. PubMed PMID: 21775007.
13. Palma D, Senan S. Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. Current opinion in oncology. 2011 Mar;23(2):133-9. PubMed PMID: 21107257.
14. Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004 Oct;126(4):1198-203. PubMed PMID: 15486383.
15. Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I nonsmall- cell lung cancer. International journal of radiation oncology, biology, physics. 2006 May 1;65(1):107-11. PubMed PMID: 16458447.
16. Hata M, Tokuuye K, Kagei K, Sugahara S, Nakayama H, Fukumitsu N, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. International journal of radiation oncology, biology, physics. 2007 Jul 1;68(3):786-93. PubMed PMID: 17379439.
17. Nakayama H, Sugahara S, Tokita M, Satoh H, Tsuboi K, Ishikawa S, et al. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba. International journal of radiation oncology, biology, physics. 2010 Oct 1;78(2):467-71. PubMed PMID: 20056349.
18. Bush DA, Cheek G, Zaheer S, Wallen J, Mirshahidi H, Katerelos A, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral earlystage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. International journal of radiation oncology, biology, physics. 2013 Aug 1;86(5):964-8. PubMed PMID: 23845845.
19. Kanemoto A, Okumura T, Ishikawa H, Mizumoto M, Oshiro Y, Kurishima K, et al. Outcomes and prognostic factors for recurrence after high-dose proton beam therapy for centrally and peripherally located stage I non--small-cell lung cancer. Clinical lung canc 5 er. 2014 Mar;15(2):e7-12. PubMed PMID: 24365049.
20. Miyamoto T, Yamamoto N, Nishimura H, Koto M, Tsujii H, Mizoe JE, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2003 Feb;66(2):127-40. PubMed PMID: 12648784.
21. Miyamoto T, Baba M, Sugane T, Nakajima M, Yashiro T, Kagei K, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2007 Oct;2(10):916-26. PubMed PMID: 17909354.
22. Miyamoto T, Baba M, Yamamoto N, Koto M, Sugawara T, Yashiro T, et al. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. International journal of radiation oncology, biology, physics. 2007 Mar 1;67(3):750-8. PubMed PMID: 17293232.
23. Sugane T, Baba M, Imai R, Nakajima M, Yamamoto N, Miyamoto T, et al. Carbon ion radiotherapy for elderly patients 80 years and older with stage I non-small cell lung cancer. Lung cancer. 2009 Apr;64(1):45-50. PubMed PMID: 18762351.
24. Iwata H, Murakami M, Demizu Y, Miyawaki D, Terashima K, Niwa Y, et al. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer. 2010 May 15;116(10):2476-85. PubMed PMID: 20225229.
25. Iwata H, Demizu Y, Fujii O, Terashima K, Mima M, Niwa Y, et al. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2bN0M0) non-small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2013 Jun;8(6):726-35. PubMed PMID: 23459403.
26. Bush DA, Slater JD, Bonnet R, Cheek GA, Dunbar RD, Moyers M, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest. 1999 Nov;116(5):1313-9. PubMed PMID: 10559093.
27. Shioyama Y, Tokuuye K, Okumura T, Kagei K, Sugahara S, Ohara K, et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2003 May 1;56(1):7-13. PubMed PMID: 12694818.
28. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA: the journal of the American Medical Association. 2010 Mar 17;303(11):1070-6. PubMed PMID: 20233825. Pubmed Central PMCID: 2907644.
29. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca 5 J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006 Oct 20;24(30):4833-9. PubMed PMID: 17050868.
30. Oshiro Y, Mizumoto M, Okumura T, Hashimoto T, Fukumitsu N, Ohkawa A, et al. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2012 Feb;7(2):370-5. PubMed PMID: 22157368.
31. Nakayama H, Satoh H, Sugahara S, Kurishima K, Tsuboi K, Sakurai H, et al. Proton beam therapy of Stage II and III non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2011 Nov 15;81(4):979-84. PubMed PMID: 20888140.
32. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15;117(20):4707-13. PubMed PMID: 21437893. Pubmed Central PMCID: 3174272.
33. Koay EJ, Lege D, Mohan R, Komaki R, Cox JD, Chang JY. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. International journal of radiation oncology, biology, physics. 2012 Dec 1;84(5):1093-100. PubMed PMID: 22543217. Pubmed Central PMCID: 3409930.
34. Xiang ZL, Erasmus J, Komaki R, Cox JD, Chang JY. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiation oncology. 2012;7:144. PubMed PMID: 22929048. Pubmed Central PMCID: 3444399.
35. Matney J, Park PC, Bluett J, Chen YP, Liu W, Court LE, et al. Effects of respiratory motion on passively scattered proton therapy versus intensity modulated photon therapy for stage III lung cancer: are proton plans more sensitive to breathing motion? International journal of radiation oncology, biology, physics. 2013 Nov 1;87(3):576-82. PubMed PMID: 24074932. Pubmed Central PMCID: 3825187.
36. Bert C, Grozinger SO, Rietzel E. Quantification of interplay effects of scanned particle beams and moving targets. Physics in medicine and biology. 2008 May 7;53(9):2253-65. PubMed PMID: 18401063.
37. Li Y, Kardar L, Li X, Li H, Cao W, Chang JY, et al. On the interplay effects with proton scanning beams in stage III lung cancer. Medical physics. 2014 Feb;41(2):021721. PubMed PMID: 24506612.
38. Grassberger C, Dowdell S, Lomax A, Sharp G, Shackleford J, Choi N, et al. Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancer. International journal of radiation oncology, biology, physics. 2013 5 Jun 1;86(2):380-6. PubMed PMID: 23462423. Pubmed Central PMCID: 3646997.
39. Dowdell S, Grassberger C, Sharp GC, Paganetti H. Interplay effects in proton scanning for lung: a 4D Monte Carlo study assessing the impact of tumor and beam delivery parameters. Physics in medicine and biology. 2013 Jun 21;58(12):4137-56. PubMed PMID: 23689035. Pubmed Central PMCID: 3752993.
40. Munck AF, Rosenschold P, Aznar MC, Nygaard DE, Persson GF, Korreman SS, Engelholm SA, et al. A treatment planning study of the potential of geometrical tracking for intensity modulated proton therapy of lung cancer. Acta oncologica. 2010 Oct;49(7):1141-8. PubMed PMID: 20831506.
41. van de Water S, Kreuger R, Zenklusen S, Hug E, Lomax AJ. Tumour tracking with scanned proton beams: assessing the accuracy and practicalities. Physics in medicine and biology. 2009 Nov 7;54(21):6549-63. PubMed PMID: 19826204.
42. Schatti A, Zakova M, Meer D, Lomax AJ. The effectiveness of combined gating and re-scanning for treating mobile targets with proton spot scanning. An experimental and simulation-based investigation. Physics in medicine and biology. 2014 Jul 21;59(14):3813-28. PubMed PMID: 24955723.
43. Liu W, Frank SJ, Li X, Li Y, Park PC, Dong L, et al. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. Medical physics. 2013 May;40(5):051711. PubMed PMID: 23635259. Pubmed Central PMCID: 3651255.
44. Engelsman M, Schwarz M, Dong L. Physics controversies in proton therapy. Seminars in radiation oncology. 2013 Apr;23(2):88-96. PubMed PMID: 23473685.
45. Stuschke M, Kaiser A, Pottgen C, Lubcke W, Farr J. Potentials of robust intensity modulated scanning proton plans for locally advanced lung cancer in comparison to intensity modulated photon plans. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2012 Jul;104(1):45-51. PubMed PMID: 22560714.
46. Unkelbach J, Bortfeld T, Martin BC, Soukup M. Reducing the sensitivity of IMPT treatment plans to setup errors and range uncertainties via probabilistic treatment planning. Medical physics. 2009 Jan;36(1):149-63. PubMed PMID: 19235384. Pubmed Central PMCID: 2673668.
47. Engelsman M, Rietzel E, Kooy HM. Four-dimensional proton treatment planning for lung tumors. International journal of radiation oncology, biology, physics. 2006 Apr 1;64(5):1589-95. PubMed PMID: 16580508.
48. Hoppe BS, Flampouri S, Henderson RH, Pham D, Bajwa AA, D'Agostino H, et al. Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results. Clinical lung cancer. 2012 Sep;13(5):352-8. PubMed PMID: 22264659.
49. Seco J, Panahandeh HR, Westover K, Adams J, Willers H. Treatment of non-small cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty. International journal of radiation oncology, biology, physics. 2012 May 1;83(1):354-61. PubMed PMID: 21985941.
50. Hui Z, Zhang X, Starkschall G, Li Y, Mohan R, Komaki R, et al. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. International journal of radiation oncology, biology, physics. 2008 Dec 1;72(5):1385-95. PubMed PMID: 18486357. Pubmed Central PMCID: 3401022.
51. Knopf AC, Boye D, Lomax A, Mori S. Adequate margin definition for scanned particle therapy in the incidence of intrafractional motion. Physics in medicine and biology. 2013 Sep 7;58(17):6079-94. PubMed PMID: 23939146.
52. Bert C, Rietzel E. 4D treatment planning for scanned ion beams. Radiation oncology. 2007;2:24. PubMed PMID: 17608919. Pubmed Central PMCID: 1952066.
53. Kase Y, Yamashita H, Fuji H, Yamamoto Y, Pu Y, Tsukishima C, et al. A treatment planning comparison of passive-scattering and intensity-modulated proton therapy for typical tumor sites. Journal of radiation research. 2012;53(2):272-80. PubMed PMID: 22129564.
54. Wang C, Nakayama H, Sugahara S, Sakae T, Tokuuye K. Comparisons of dose-volume histograms for proton-beam versus 3-D conformal x-ray therapy in patients with stage I non-small cell lung cancer. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2009 Apr;185(4):231-4. PubMed PMID: 19370425.
55. Macdonald OK, Kruse JJ, Miller JM, Garces YI, Brown PD, Miller RC, et al. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis. International journal of radiation oncology, biology, physics. 2009 Nov 1;75(3):950-8. PubMed PMID: 19801106.
56. Kadoya N, Obata Y, Kato T, Kagiya M, Nakamura T, Tomoda T, et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2011 Mar 15;79(4):1225-31. PubMed PMID: 20732759.
57. Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2011 Jul 15;80(4):1015-22. PubMed PMID: 20615629. Pubmed Central PMCID: 2952351.
58. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2006 Jul 15;65(4):1087-96. PubMed PMID: 16682145.
59. Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. International journal of radiation oncology, biology, physics. 2010 Jun 1;77(2):357-66. PubMed PMID: 19660879. Pubmed Central PMCID: 2868090.
60. Nichols RC, Huh SN, Henderson RH, Mendenhall NP, Flampouri S, Li Z, et al. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric study. Clinical lung cancer. 2011 Jul;12(4):252-7. PubMed PMID: 21726825.